[ 1 ] FDA approval brings first gene therapy to the United States [Internet]. Silver Spring: US Food and Drug Administration; 2017 Aug 30 [updated 2018 Mar 26; cited 2018 Jul 22]. Available from: https://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm574058.htm.

[ 2 ] Bartfai T, Lees GV. Drug discovery: from bedside to Wall Street. Burlington: Academic Press; 2006. link1

[ 3 ] Bartfai T, Lees GV. The future of drug discovery: who decides which diseases to treat? Burlington: Academic Press; 2013. link1

[ 4 ] Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991;324 (10):667–74. link1

[ 5 ] Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986;233(4770):1318–21. link1

[ 6 ] Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988;319(25):1676–80. link1

[ 7 ] Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314(5796):126–9. link1

[ 8 ] Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 1989;86(24):10024–8. link1

[ 9 ] Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3 (95):95ra73. link1

[10] Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013;5(177):177ra38. link1

[11] Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371(16):1507–17. link1

[12] Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+ :CD8+ composition in adult B cell ALL patients. J Clin Invest 2016;126(6):2123–38. link1

[13] Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014;124(2):188–95. link1

[14] Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell 2017;168(4):724–40. link1